? PROTOCOL REVIEW AND MONITORING SYSTEM The Protocol Review and Monitoring System (PRMS) for the Tisch Cancer Institute (TCI) oversees all cancer related clinical research at Mount Sinai in order to ensure that it is of the highest scientific merit and that TCI resources are used efficiently. The PRMS consists of the Protocol Review and Monitoring Committee (PRMC) and the Scientific Progress and Accrual Review Committee (SPARC), a subcommittee of the PRMC. The PRMC review process ensures that all research is safe and scientifically sound with entry criteria that reflect our patient population, have a high probability of full accrual, do not compete with each other, have adequate resources to answer the question being asked, and is consistent with the priorities of the TCI. The SPARC review process monitors active protocols for continued scientific merit, progress, and accrual. Pre-PRMS evaluations are completed by the Disease Focus Groups (DFG) and the Data Safety and Monitoring Committee (DSMC). If applicable, protocols also receive a Resource Allocation Evaluation (RAE). The outcome from each of these evaluations is submitted to the PRMC for reference, ensuring that each protocol receives a thorough, high quality peer review. The PRMC review occurs prior to the submission to the Institutional Review Board (IRB). PRMS functions are independent of the IRB, and do not duplicate or overlap with the responsibilities of the IRB. The PRMS has the authority to open protocols that meet the scientific merit and priorities of the TCI and to terminate protocols that do not demonstrate scientific progress.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Icahn School of Medicine at Mount Sinai
New York
United States
Zip Code
Hogstad, Brandon; Berres, Marie-Luise; Chakraborty, Rikhia et al. (2018) RAF/MEK/extracellular signal-related kinase pathway suppresses dendritic cell migration and traps dendritic cells in Langerhans cell histiocytosis lesions. J Exp Med 215:319-336
Fujiwara, Naoto; Nakagawa, Hayato; Enooku, Kenichiro et al. (2018) CPT2 downregulation adapts HCC to lipid-rich environment and promotes carcinogenesis via acylcarnitine accumulation in obesity. Gut 67:1493-1504
Chang, Sanders; Ru, Meng; Moshier, Erin L et al. (2018) The impact of radiation treatment planning technique on unplanned hospital admissions. Adv Radiat Oncol 3:647-654
Wu, Lisa M; Amidi, Ali; Tanenbaum, Molly L et al. (2018) Computerized cognitive training in prostate cancer patients on androgen deprivation therapy: a pilot study. Support Care Cancer 26:1917-1926
Likhterov, Ilya; Ru, Meng; Ganz, Cindy et al. (2018) Objective and subjective hyposalivation after treatment for head and neck cancer: Long-term outcomes. Laryngoscope 128:2732-2739
Formenti, Silvia C; Rudqvist, Nils-Petter; Golden, Encouse et al. (2018) Radiotherapy induces responses of lung cancer to CTLA-4 blockade. Nat Med 24:1845-1851
Sun, Zhen; Filipescu, Dan; Andrade, Joshua et al. (2018) Transcription-associated histone pruning demarcates macroH2A chromatin domains. Nat Struct Mol Biol 25:958-970
Strub, Thomas; Ghiraldini, Flavia G; Carcamo, Saul et al. (2018) SIRT6 haploinsufficiency induces BRAFV600E melanoma cell resistance to MAPK inhibitors via IGF signalling. Nat Commun 9:3440
Buckstein, M; Rhome, R; Ru, M et al. (2018) Neoadjuvant chemoradiation radiation dose levels for surgically resectable esophageal cancer: predictors of use and outcomes. Dis Esophagus 31:
Kamath, Geetanjali R; Taioli, Emanuela; N Egorova, Natalia et al. (2018) Liver Cancer Disparities in New York City: A Neighborhood View of Risk and Harm Reduction Factors. Front Oncol 8:220

Showing the most recent 10 out of 143 publications